Thank you, Sarah, and good afternoon, everyone. I would like to thank you all for joining our Q2 2020 shareholder call. This has certainly been an unusual quarter, one where the world has changed in the way that none of us could have anticipated. Many businesses and millions of people have been hit hard by the COVID-19 pandemic. We've all had to learn how to interact and conduct business in a new environment and in a very different manner.
For many, survival has been the goal during the past six months.
So it is within that context, I'm delighted to share with you some incredible progress that our company has made in the second quarter of this year.
During this call, I'll provide our investors with a quick overview of our company core businesses, and share the progress we're making in each of those businesses. I'll also discuss some of our plans going forward as well as, of course, address and COVID-19 initiative. But before that, for the sake of many of our new shareholders, let me begin with our company vision because that's what drives all of us. We started Precipio almost a decade ago with a vision of building a company to battle the unacceptable problem of disease misdiagnosis. We decided to focus on the scariest word in healthcare, cancer, and attempt to make an impact on patients' lives. Within cancer, we focus on blood-related cancers which according to numerous publications reaches rate of misdiagnosis as high as 25%.
Over the years, we developed a platform that combines the highest quality of laboratory professionalism, advanced technologies, and academic expertise with world leading institutions. The company's dedicated focus and hard work has resulted in delivering a diagnostic accuracy rate of close to 100%.
Our business is built of two core areas.
The first is our pathology services, and the second is the product side of our business.
Let's begin with our product pathology services. We provide clinical diagnostic services to our customers who are oncologists and hospitals benefiting from the combination of our CLIA certified specialized laboratory and our expert subspecialist academic pathologists. We employ a dedicated sales team that goes out to our customers and presents our value proposition. And as you can see from this quarter results and our previous quarter, even under the current environment, we continue to rapidly grow this business.
During Q2, we successfully executed on the transition of the Oncometrix customers and their integration into our company. The increase in our customer base along with the addition of many new customers has impacted the growth we shared with you in our recent filing.
Going forward, the diagnostic services side of our business is tasked with one goal, continued rapid growth in order to scale up and reach profitability.
As the company continues to increase its volume, margins will improve which drives cash to the bottom-line. We believe that the results we see are testimony to the success of our team in sharing our value proposition and the market acceptance and the quality we deliver to oncologists and to their patients. With that progress, we move closer and closer to the goal of reaching profitability.
The second part of our business is the product side.
Over the course of the years as we upgraded our laboratory to the diagnostic services we provide, we identified several opportunities to improve both the accuracy and efficiency of laboratory processes by developing novel technologies. IV-Cell and HemeScreen are two examples of those technologies which we developed, patented and have been successfully used in our laboratory for the past couple of years. Last year, we began to commercialize our IV-Cell and HemeScreen technologies and bring them to market, so that not only are patients being diagnosed in our labs with benefits of these improvements, or rather that other laboratories could also implement the same technologies, achieving broader impact to both for patient care as well as financial benefits for the company. Like any new product being introduced to the market, there are always bumps on the road and things you learn from that process.
Fortunately, we are an adaptive company. We've listened to the market and addressed this issue. I'd like to discuss some of the changes we've made over the past six months.
First, with IV-Cell, we received feedback from some of the major laboratories we're working within the market. And as mentioned previously, we embarked on the development and launch of Version 2 of the media. We're going through the final stages of testing and expect to have a market ready product by year end.
Additionally, we've been exploring several strategic partnerships in order to utilize existing distribution channels to bring this product to market. We believe that Version 2 will provide even more value to the laboratories we've been working with.
We also believe that a distribution partnership with a company that is already selling into these large laboratories is the right way to go in terms of quickly bringing the product to market by leveraging an existing salesforce, distribution channel, rather than building our own.
Our goal is to accelerate the adoption of our product in the market.
We expect to share with you in the near future more on this strategic partnership and our go to market strategy for IV-Cell. With respect to HemeScreen, in addition to our target customer segment of laboratories, we've identified a new segment, the physician office laboratory. And particularly due to COVID-19, physician offices have been struggling to improve their quality of service, efficiency and generate additional revenue.
Our HemeScreen Reagent Rental model provides the perfect solution.
Our internal sales team has already onboarded several customers and we have a strong pipeline. With HemeScreen as well, in addition to our internal sales efforts, we've recognized that developing a strategic partnership with a major player that has an existing distribution channel in the segment can be advantageous to a rapid introduction of our products to the market. Therefore, much like with IV-Cell, we anticipate developing research and good partnerships to accelerate the penetration of our products into the market. We believe that the next 12 months will show alongside continued growth for both businesses a substantial shift in the balance of revenue between diagnostic services and product sales. And given the product side of the business delivers very healthy margins and cash flow, we expect that to have a significant impact on the company's financials.
Now, let me turn to our COVID-19 testing initiatives. I know there were many questions about the technology, regulatory and business landscape.
So let me try and address some of those questions that were sent in and then discuss our market rollout. I'll begin with the regulatory landscape. In ordinary times when a company wishes to submit a product for FDA approval, the typical timeline for the processing of the submission is up to and including potential approval of the product by FDA may take anywhere from two to five years.
During the COVID-19 pandemic, the FDA utilized the Emergency Use Authorization process called EUA and created an accelerated process to grant authorization to companies wishing to develop and rapidly introduce serology and other tests to the market.
During the first few months in the pandemic breakout early this year, the FDA issued several EUA permits to various types of diagnostic tools for detecting either the presence of the virus or the presence of antibodies. There are two main types of diagnostic tests for COVID-19.
The first is the steps for the presence of the virus. This is usually done by collecting a sample, using a nasal swab and recently there have been a few new products that use a saliva sample. Those samples are collected and sent into a laboratory, which typically runs the test using a testing platform called PCR. This test indicates whether the person has contracted the virus at the time of the test. It does not indicate whether the person will develop symptoms or get sick. It only indicates if the person has contracted the virus.
The second test type is the antibody test. This is the one we took interest in. Once the body has been exposed to a virus, it begins developing its defense mechanism, which includes the creation of antibodies. Simply put, initially those antibodies will work to get rid of the virus present in the person's body. But after that, the body creates antibodies that form a type of preventative shield, if you will, so that if the person is ever exposed again to the same virus, this shield will keep the virus out and not allow for infection. This is basically the so-called immunity. Research has shown that the antibodies typically appear in the body anywhere from one to three weeks after exposure to the virus and that they remain in various levels in the body long-term.
So in theory, the presence of antibodies will indicate that the person is immune and therefore will neither contract nor transmit virus. Needless to say, this information would have vast implications on the society's ability to open the economy and resume some form of normalcy. The test has been conducted by a blood sample. And as of now, the FDA has authorized testing only in the laboratory setting. Therefore, people wishing to be tested must get a blood drawn. And the sample is sent to the lab for testing.
For our test, the testing time from start to getting result is approximately 10 minutes. The test was designed to be used both in the laboratory environment, in a point-of-care or for self-use. It's important to amplify that as of now the FDA has authorized it only for use in the lab. We initially began working with a company who had filed for EUA approval with the FDA for its serology test.
As the process proceeded, we began to realize that there were question marks around their product receiving EUA and so we put to develop a plan B, which we recently executed on.
As we recently announced, we’ve partnered with ADS Biotec by signing an agreement with them to distribute the FDA authorized COVID-19 serology antibody test in the U.S. as well as other markets worldwide.
As mentioned, the FDA is currently providing EUA authorization only for the tests that are conducted strictly with a laboratory setting. Therefore, our first step was to offer the test to our pathology customers, the first customer base who provide this test to their patients coming into the practice every day.
The first step was launched a couple weeks ago and has received strong acceptance.
However, it's no secret that there's a huge gap between laboratory capacity in the U.S. and the number of tests needed in order to enable the economy in the U.S. and worldwide to reopen, and for all of us to resume a normal course of life. We strongly believe that the next natural and logical step to reopen the economy will be for the FDA to expand the EUA authorization to both point-of-care and ultimately to allow for self-use of these tests.
Our serology test was designed to ultimately serve as a self-administered test and we believe our product is well-positioned to serve that demand.
Over the next few weeks, we will be completing the study that we began a couple of months ago in order to demonstrate the quality of our tests in a point-of-care and self-use environment.
We are confident in our product’s ability to meet the necessary standards that the FDA has outlined for these applications. Many of you have asked why we haven't shared the results of the study? Part of the reason is that the study is not yet complete. But initially, the FDA also frowned upon companies publicizing results before allowing the FDA to review them first. Therefore, we want to make sure we follow the processes outlined by the FDA. And then we comply with their requirements before we provide additional information to the public on the study results. We don't know when the FDA will expand the utility to these tests and allow companies to submit applications for expanded use for point-of-care and self-use.
However, we believe based on the dialogue with the FDA that this is a question of when, not an if.
Our goal is to be in a position to have the data from our study ready and to hit the go button as soon as the FDA opens up this option. From a production capacity, we are currently able to generate 1 million tests per day. In parallel, we will be lining up various distribution channels for these new potential use of the test kits for both point-of-care as well as self-use, so that once we have expanded EUA for these applications received, we will have distribution in place and ready to go. In many ways, the COVID initiative can be viewed by some as a distraction from our core business.
As you can see from our quarterly results and by the ongoing growth this quarter as well, I hope our shareholders appreciate that we have not taken our eye off the ball with respect to our core business, and continue to grow in those areas of our business alongside our COVID initiative.
However, we also believe that this could be a huge opportunity to generate value for shareholders. Furthermore, we feel that as a member of the healthcare community and a diagnostic company, we have a responsibility to contribute to the battle given the tremendous testing deficiency in the U.S. In summary, I feel we’ve positioned our company not only to overcome the challenges we face in the new world we live in but we're also in a position to capitalize on the situation, gain market share and bring our products to market in an economically advantageous manner. Midway through the summer, we continue to see the same growth levels and we feel that the contribution that COVID testing will bring to our business and to our bottom-line may be a tremendous opportunity.
We will continue to work hard throughout this quarter and ongoing to deliver the expectations of our company and to realize our potential of the revenue growth and shareholder value. I want to thank you for your ongoing support and wish you and your families, health and safety. Thank you and have a nice evening.